BidaskClub Upgrades Uniqure (NASDAQ:QURE) to Buy

Uniqure (NASDAQ:QURE) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a report released on Wednesday, BidAskClub reports.

Other research analysts also recently issued reports about the company. HC Wainwright reiterated a “buy” rating and issued a $73.00 target price on shares of Uniqure in a research note on Monday, October 14th. Guggenheim downgraded Uniqure from a “buy” rating to a “neutral” rating in a research note on Monday, July 29th. Credit Suisse Group initiated coverage on Uniqure in a research note on Tuesday, November 5th. They issued an “outperform” rating and a $76.00 target price on the stock. Zacks Investment Research upgraded Uniqure from a “hold” rating to a “buy” rating and set a $42.00 target price on the stock in a research note on Thursday, October 3rd. Finally, Stifel Nicolaus initiated coverage on Uniqure in a research note on Friday, October 11th. They issued a “buy” rating and a $79.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $74.53.

QURE traded down $0.16 during trading on Wednesday, hitting $53.81. 235,700 shares of the stock were exchanged, compared to its average volume of 583,255. The firm has a market capitalization of $2.34 billion, a P/E ratio of -23.00 and a beta of 0.84. Uniqure has a 1-year low of $21.98 and a 1-year high of $82.49. The stock has a fifty day moving average price of $45.58 and a two-hundred day moving average price of $58.07. The company has a quick ratio of 14.33, a current ratio of 14.33 and a debt-to-equity ratio of 0.19.

Uniqure (NASDAQ:QURE) last released its quarterly earnings results on Monday, October 28th. The biotechnology company reported ($0.58) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.23. The company had revenue of $1.05 million for the quarter, compared to analyst estimates of $2.24 million. Uniqure had a negative return on equity of 51.12% and a negative net margin of 1,670.86%. Analysts predict that Uniqure will post -3 EPS for the current year.

In related news, CEO Matthew C. Kapusta sold 8,000 shares of Uniqure stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $56.48, for a total value of $451,840.00. Following the sale, the chief executive officer now directly owns 391,230 shares in the company, valued at $22,096,670.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Robert Gut sold 4,769 shares of Uniqure stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $47.16, for a total value of $224,906.04. Following the completion of the sale, the insider now owns 35,378 shares in the company, valued at $1,668,426.48. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 36,769 shares of company stock worth $1,759,426. Company insiders own 2.91% of the company’s stock.

Several institutional investors have recently bought and sold shares of the stock. Sanders Morris Harris LLC bought a new stake in Uniqure during the 2nd quarter worth approximately $3,084,000. First Citizens Bank & Trust Co. bought a new stake in shares of Uniqure during the second quarter valued at approximately $211,000. Xact Kapitalforvaltning AB bought a new stake in shares of Uniqure during the second quarter valued at approximately $328,000. Henry James International Management Inc. raised its position in shares of Uniqure by 16.6% during the second quarter. Henry James International Management Inc. now owns 105,844 shares of the biotechnology company’s stock valued at $8,272,000 after buying an additional 15,058 shares during the last quarter. Finally, Eqis Capital Management Inc. raised its position in shares of Uniqure by 14.2% during the second quarter. Eqis Capital Management Inc. now owns 27,126 shares of the biotechnology company’s stock valued at $2,120,000 after buying an additional 3,379 shares during the last quarter. Hedge funds and other institutional investors own 62.81% of the company’s stock.

About Uniqure

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.

Further Reading: What is Considered a Good Return on Equity (ROE)?

Analyst Recommendations for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.